Blood Pressure Reduction and Cardiovascular Prevention: An Update Including the 2003-2004 Secondary Prevention Trials
View Full Paper
Ask AI
Bookmark
Share
Key result
New antihypertensive drugs provided similar protection against total mortality compared to conventional therapy, with cardiovascular outcomes largely explained by the degree of systolic blood pressure reduction.
Why the study?
Do new antihypertensive drugs improve cardiovascular outcomes compared to old drugs or placebo beyond their blood pressure-lowering effects in hypertensive or high-risk patients?
Population
Hypertensive or high-risk patients from clinical trials published before 2005
Comparison
New antihypertensive drugs vs Old antihypertensive drugs or placebo
Design
Meta-analysis
Authors
Discussion
Loading...
Member takes
Overview
Focus on systolic BP targets over drug class; confirms 2003 meta-analysis equivalence for mortality.
Study Design
Type
Meta-Analysis (n=149,407)
Structured PICO
Do new antihypertensive drugs improve cardiovascular outcomes compared to old drugs or placebo beyond their blood pressure-lowering effects in hypertensive or high-risk patients?
P
Population
Hypertensive or high-risk patients from clinical trials published before 2005 (meta-analysis including 30 trials with 149,407 randomized patients in meta-regression, and 15 trials with 120,574 patients comparing new vs old drugs)
I
Intervention
New antihypertensive drugs (calcium-channel blockers, ACE inhibitors, angiotensin II type 1 receptor blockers)
C
Comparator
Old antihypertensive drugs (diuretics, beta-blockers) or placebo
O
Outcome
Cardiovascular outcomes (composite of all cardiovascular events, fatal and non-fatal stroke, fatal and non-fatal myocardial infarction, and heart failure)hard clinical
Main Result
Effect estimate: OR 0.98 (95% CI 0.94-1.02)
p-value: p=0.38
The cardiovascular benefits of newer antihypertensive agents are predominantly driven by the magnitude of systolic blood pressure reduction rather than drug-specific pleiotropic properties.
Limitations
- Use of composite endpoints with varying definitions across trials
- Wide range of secondary endpoints made obtaining pooled estimates difficult
Cite This Study
Staessen et al. (2005) conducted a meta-analysis in Hypertension and high cardiovascular risk (n=149,407). New antihypertensive drugs (calcium-channel blockers, ACE inhibitors, AR1 blockers) vs. Conventional therapy (diuretics, beta-blockers) or placebo was evaluated on Total mortality (new vs. old antihypertensive drugs) (OR 0.98, 95% CI 0.94-1.02, p=0.38). New antihypertensive drugs provided similar protection against total mortality compared to conventional therapy, with cardiovascular outcomes largely explained by the degree of systolic blood pressure reduction.
Topics
View Full Paper
Ask AI
Bookmark
Share